MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

RO4987655

CAS No. : 874101-00-5

MCE 站：RO4987655

产品活性：RO4987655 是一种具有口服活性的选择性 MEK 抑制剂，抑制 MEK1/MEK2，IC₅₀ 为 5.2 nM。

研究领域：MAPK/ERK Pathway

作用靶点：MEK

In Vitro: RO4987655 potently inhibits mitogen-activated protein kinase signaling pathway activation and tumor cell growth, with an in vitro IC₅₀ of 5.2 nM for inhibition of MEK1/2. RO4987655 inhibits proliferation of NCI-H2122 cells in a dose-dependent manner with an IC₅₀ value of 0.0065 μM. RO4987655 at doses ranging from 0.1 to 1.0 μM suppresses pERK1/2 already at 2 h after the start of treatment.

In Vivo: Single-agent oral administration of RO4987655 (CH4987655) results in complete tumor regressions in xenograft models. RO4987655 is rapidly absorbed with a t_max of ~1 h. Exposures are dose proportional from 0.5 to 4 mg. The disposition is biphasic with a terminal t_1/2 of ~25 hr. Intersubject variability is low, 9% to 23% for C_max and 14% to 25% for area-under-the-curve (AUC). pERK inhibition is exposure dependent and is greater than 80% inhibition at higher doses. The pharmacokinetic-pharmacodynamic relationship is characterized by an inhibitory E_max model (E_max ~100%; IC₅₀ 40.6 ng/mL) using nonlinear mixed-effect modeling. Female athymic nude mice are randomized into study groups. The tumors size is estimated with digital caliper and PET scans performed on days 0, 1, and 3 with 1.0, 2.5, and 5.0 mg/kg RO4987655. The vehicle treatment does not inhibit the NCI-H2122 tumor xenograft growth over this time frame. In contrast, RO4987655 treatment results in 119% tumor growth inhibition (TGI) at 1.0 mg/kg, 145% TGI at 2.5 mg/kg and 150% TGI at 5.0 mg/kg on day 3. PET imaging shows that [¹⁸F] FDG uptake in the xenografts decreases within 24 h (day 1) from the administration of RO4987655.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Endoplasmic Reticulum Stress Compound Library  |  Orally Active Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  PD98059  |  U0126-EtOH  |  Binimetinib  |  Isorhamnetin  |  BIX02189  |  Ro 5126766  |  CI-1040  |  Lidocaine  |  trans-Zeatin  |  BIX02188  |  SL327  |  C16-PAF  |  GW284543  |  MEK inhibitor  |  Gossypetin  |  Hypothemycin  |  Anemarsaponin B  |  PD0325901-O-C2-dioxolane  |  MEK-IN-1  |  Xantocillin

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。